JAK Inhibitors and Safety
|
|
- Ross Mitchell
- 6 years ago
- Views:
Transcription
1 JAK Inhibitors and Safety Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health, and Preventive Medicine Oregon Health & Science University
2 Learning Objectives Discuss recent clinical trial and real world data from approved and investigational JAK inhibitors Review safety profiles of approved and investigational JAK inhibitors across the spectrum of rheumatoid arthritis
3 Clark JD, et al. J Med Chem
4 Winthrop KL. Nat Rheum Rev
5 Clark JD, et al. J Med Chem
6 Winthrop KL. Nat Rheum Rev
7 Tofacitinib (Tofa) and Lipids Charle-Schoeman C, et al. ACR Abstract #487.
8 Malignancy and Tofa Curtis J, et al. ARD
9 IR (events/100 pt-yrs [95% CI]) Incidence Rates of Serious Infections by 6-Month Intervals to 6 6 to to to to to to 42 >42 Reproduced with permission. Months Overall rate of serious infection reported with tofacitinib: 3.1 events/100 patient-years Rates previously reported in clinical trial safety analyses of other RA drugs: Adalimumab events/ 100 patient-years Rituximab events/ 100 patient-years Tocilizumab events/ 100 patient-years Etanercept 3.8 events/100 patient-years Abatacept events/100 patient-years Golimumab 5.09 events/100 patient-years Cohen S, Radominski SC, Gomez-Reino JJ, et al. Arthritis Rheumatol Jul 21. [Epub ahead of print]. Slide prepared by CSF.
10 Risk Factors for Serious Infection Cohen S, et al. Arthritis Rheumatol
11 Tofa and Opportunistic Infections (P2P3LTE) 60 OIs reported (IR 0.46/100 pys [ ]) TB (n=26) PCP (n=4) CMV (n=6) Candida Esophagitis (n=9) Cryptococcus (n=3) NTM (n=2) HZ, multi-dermatomal (n=8) BK encephalopathy (n=1) Toxoplasmosis (n=1) Winthrop K, et al. ARD
12 Herpes Zoster and JAK Inihibition Winthrop, et al. Arth and Rheumatol
13 Winthrop K, et al. EULAR
14 Real World HZ with Tofa and Biologics Curtis J, et al. ARD
15 Real World HZ and HSV with Tofa and Biologics Curtis J, et al. ARD
16 HZ in Tofa-treated PsO Tofacitinib 10mg BID dose is not approved Winthrop KL, et al. Fall Clinical Derm Congress. (abstract) 2015.
17 Polymorphism for HZ 5,246 Tofa-treated RA patients Genome-wide screen Adjusted for age, baseline lymphocyte, and MTX use Outcome modeled Time to HZ and HZ incidence CD83, OR 3.7, p=2.1 X 10-8 (allelle freq only 3% whites, <0.1% Japanese) IL-17RB, HR 3.6, p = 7.6 X (allelle freq only <0.2% whites, 17% Japanese) Bing N, et al. ACR. abstract 2015.
18 JAKi and GI Perforation: Tofa in Real World Other JAKi Baricitinib development program with 2 GI perforations (5/1,000 patient-years) Xie F, et al. ARD. 2016; Smolen JS, et al. EULAR 2016.
19 Tofa Diminishes NK Cell Activation Nocturne G, et al. ACR Abstract
20 Tofa Decreases B Cell Activation Wang S-P, et al. ARD
21 Tofa Inhibits CD4 Proliferation in RA Patients Maeshima, et al. Arth Rheum
22 Baricitinib JAK 1,2 Approved in Europe for RA 2mg and 4mg once daily doses
23 Lymphocyte Decline Wollenhaupt J, et al. J Rheum
24 Emery P, et al. ACR
25 Emery P, et al. ACR
26 SIE and Baricitinib Smolen JS, et al. EULAR
27 HZ and Baricitinib Smolen JS, et al. EULAR
28 HZ and Bari by Region Winthrop KL, et al. ACR abstract
29 TNFi and Baricitinib: A Look During the Overlap Tayler PC, et al. ACR abstract.
30 Malignancy and Baricitinib (Excluding NMSC) Smolen JS, et al. EULAR
31 Ruxolitinib---JAK1/JAK2 Inhibitor (Asia) Wong Jun C, et al. Leukemia and Lympoma
32 PML Wathes R, et al. NEJM
33 JAK 1 Race Filgotinib ABT-494 ( Upa )
34 Potency and Selectivity of Filgotinib in JAK Biochemical Assays Recombinant human kinase IC50 (nm, ± SEM; n = 2 4) Kd (nm) JAK1 10 ± JAK2 28 ± JAK3 810 ± TYK2 116 ± 39 ND GLPG0634 preferentially inhibits JAK/STAT signalling involving JAK1 than JAK2 kinase in a cellular context IC 50 values for inhibition of recombinant JAK1, JAK2, JAK3, and TYK2 by GLPG0634 were determined by measuring the incorporation of phosphate into an ULight-JAK-1(Tyr1023) peptide using an europium-labelled antiphosphotyrosine Ab. The Kd values of GLPG0634 on JAK1, JAK2, and JAK3 were determined by measuring the competition of GLPG0634 with a fluorescently labelled ATP mimetic. IC 50 values corresponding to 50% probe displacement were obtained and Kd values calculated according to the Cheng Prusoff equation. CIA, collagen-induced arthritis; QD, once daily Reproduced with permission from Van Rompaey, et al. J Immunol. 2013;191: slide prepared by CSF.
35 GLPG0634-JAK 1 Selective Dose ranging study (phase 2b), 285 RA patients No increase in LDL-cholesterol No LFT rise Modest decrease in neutrophils and platelets No change in CD8, NK, or RBC counts Small increase in creatinine, hemoglobin In vitro, GLPG0634 and main metabolite No induction of CYP1A2, CYP2B6 and CYP3A4 enzymes No difference in midazolam pharmacokinetics Little clinical data yet reported Vanhoutte F, et al. ACR ; Namopur F, et al. ACR Abstract. #1481, 2014; Galien R, et al. ACR abstract 2781.
36 ABT-494 in RA TNF-IR (Phase 2b) JAK 1 inhibitor ABT-494 Number of pts, n (%) PBO (n=56) 3 mg BID (n=55) 6 mg BID (n=55) 12 mg BID (n=55) 18 mg BID (n=55) Serious AE 1 (2) 2 (4) 2 (4) 0 1 (2) Infections 13 (23) 11 (20) 12 (22) 22 (40) 21 (38) Serious infection 1 (2) Anemia (2) Herpes zoster 2 (4) 1 (2) 0 1 (2) 1 (2) Hepatic disorder 1 (2) (4) Neutropenia (2) 1 (2) Malignancy (2) 0 0 Kremer J, et al. ACR. Later-breaker 2015.
37 Vaccination prior to JAK Inhibition Winthrop KL, et al. ACR late breaker poster #12L.
38 Winthrop KL, et al. ACR late breaker poster #12L.
39 Disseminated Vaccine Winthrop KL, et al. ACR late breaker poster #12L.
40 Pneumococcal antibody GMFR (95% CI) Tofacitinib and PPSV PBO PBO + MTX 16 Tofacitinib 10 mg BID Tofacitinib 10 mg BID + MTX B 7F 9V 14 18C 19A 19F 23F Pneumococcal Antigen Serotype Winthrop K, et al. EULAR. abstract 2013.
41 Responders (%) Tofacitinib and Trivalaent Influenza Vaccine 100 PBO Tofacitinib 10 mg BID Winthrop K, et al. EULAR. abstract Overall Without Methotrexate 41 With Methotrexate Response defined by 4-fold increase in antibody titers in 2 of 3 influenza antigens
42 Tofacitinib and Ruxolitinib Inhibit HIV Replication Gavegnano, et al. Antimicrobial Agents and Chemotherapy
43 Acknowledgements UAB colleagues ACR and EULAR colleagues Oregon Health Authority colleagues CDC colleagues
Opportunistic Infections and Tuberculosis Risk Management
Opportunistic Infections and Tuberculosis Risk Management Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health, and Preventive Medicine Oregon Health & Science
More informationTuberculosis and Biologic Therapies: Risk and Prevention
Tuberculosis and Biologic Therapies: Risk and Prevention Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health and Preventive Medicine Oregon Health & Science
More information11/5/2011. Disclosures. Key References. JAK Inhibitors. Tofacitinib(CP ): Phase 2 Studies
Disclosures KINASE INHIBITORS IN RA Michael E. Weinblatt, M.D. Dr. Weinblatt has been a consultant to the following companies involved in the JAK and SYK pathways in RA Pfizer Vertex Astellas Rigel Astra-Zeneca
More informationAmerican College of Rheumatology Analyst and Investor Meeting November 6, 2011
American College of Rheumatology 2011 Analyst and Investor Meeting November 6, 2011 Chuck Triano Senior Vice President, Investor Relations Forward-Looking Statements Our discussions during this meeting
More informationLong-term Safety of Tofacitinib for the Treatment of Rheumatoid Arthritis up to 8.5 years:
Long-term Safety of Tofacitinib for the Treatment of Rheumatoid Arthritis up to 8.5 years: Integrated Analysis of Data from the Global Clinical Trials SUPPLEMENTARY TEXT Case ascertainment for gastrointestinal
More informationEfficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis; results of a phase IIA trial
Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis; results of a phase IIA trial Frédéric Vanhoutte, MD Minodora Mazur, MD, PhD EULAR 09 June
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRERIBING COMMITTEE (JAPC) Derbyshire commissioning guidance on biologic drugs f the treatment of Rheumatoid arthritis with methotrexate This algithm is a tool to aid the implementation
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationGalapagos Mechelen, Belgium, and Romainville, France. Digestive Disease Week 2014 pres# 188 Saturday, May 3
Exploration of GLPG0634, the first selective JAK1 inhibitor, in Inflammatory Bowel Disease is supported by early clinical results and mouse DSS-colitis data René Galien, Didier Merciris, Frédéric Vanhoutte,
More informationJAK-INHIBITORER MODE OF ACTION
JAK-INHIBITORER MODE OF ACTION DANBIO KURSUS 19. JANUAR 2018 Uffe Møller Døhn Center for Rheumatology and Spine Diseases & COPECARE Rigshospitalet, Glostrup Denmark RA PATHOGENESIS Rheumatoid arthritis
More informationWelcome to Rheumatology Highlights Report; I m Dr. Len Calabrese from the R.J. Fasenmyer Center for Clinical Immunology. And, in the next 15 minutes
Welcome to Rheumatology Highlights Report; I m Dr. Len Calabrese from the R.J. Fasenmyer Center for Clinical Immunology. And, in the next 15 minutes I m going to update you on the safety of biologics.
More informationClinical Trial Report
The JAK inhibitor tofacitinib for active rheumatoid arthritis: results from Phase III trials Tofacitinib is a Janus kinase inhibitor that modulates the transcription of cytokine genes involved in immune
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More information- Clinical Background, Motivation and my Experience at F2F meeting
Predicting randomized clinical trial results with realworld evidence: A case study in the comparative safety of tofacitinib, adalimumab and etanercept in patients with rheumatoid arthritis - Clinical Background,
More informationOlumiant (baricitinib) NEW PRODUCT SLIDESHOW
Olumiant (baricitinib) NEW PRODUCT SLIDESHOW Introduction Brand name: Olumiant Generic name: Baricitinib Pharmacological class: Janus kinase (JAK) inhibitor Strength and Formulation: 2mg; tabs Manufacturer:
More informationReal-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis Jeffrey R Curtis, Fenglong Xie, Huifeng Yun, Sasha Bernatsky, Kevin L Winthrop
More information(tofacitinib) are met.
Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically
More informationInfections and Biologics
Overview Infections and Biologics James Galloway What is the risk of infection with biologics? Are some patients at greater risk? Are some drugs safer? Case scenario You recently commenced Judith, a 54
More informationJames R. O Dell, M.D. University of Nebraska Medical Center
Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationSummary of Risk Minimization Measures
Table 6.1.4-1: Summary of Risk Minimization Measures Safety Concern Vaccination Hepatic and renal impairment Combination therapy Elderly Routine Risk Minimization Measures Specific subsection on vaccination
More information8/5/2015. Methods. Activity presentations are considered intellectual property.
Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful
More informationRheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy
Rheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy [ Cuando iniciar o detener la tx anti-tnf?] Asociacion Costatarricense Medicina Interna August 7, 2015 Arthur Weinstein, MD, FACP,
More informationJAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical
Mod Rheumatol (2013) 23:415 424 DOI 10.1007/s10165-012-0799-2 REVIEW ARTICLE JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical Yoshiya Tanaka Kunihiro Yamaoka Received:
More informationPractical RA Treatment: James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014
Practical RA Treatment: 2014 James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014 Disclosures James R. O Dell PI of Multinational RA trial supported by VA and NIH (NIAMS) that receives
More informationKinase inhibitors in rheumatoid arthritis: JAK/ STAT signaling pathway
Kinase inhibitors in rheumatoid arthritis: JAK/ STAT signaling pathway Professor Peter C. Taylor MA, PhD, FRCP Tyrosine Kinase Inhibitors in Health and Rheumatic Diseases Ankara, Turkey. 12 March 211 Cytokines
More informationNew Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab
New Evidence reports on presentations given at ACR 2009 Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab From ACR 2009: Rituximab Rituximab in combination with methotrexate
More informationProliferation of Medications
Proliferation of Medications Novel Biologic Therapies for Rheumatic Diseases: An Overview Jonathan Graf, MD Professor of Clinical Medicine, UCSF Division of Rheumatology San Francisco General Hospital
More informationRheumatoid Arthritis and the Changing Canadian Landscape
Rheumatoid Arthritis and the Changing Canadian Landscape This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians
More informationLong-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Handling editor Tore K Kvien Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ annrheumdis-2016-210457). For numbered affiliations see end
More informationSynoviocytes. Macrophage. B cell C H R O N I C. Neutrophil. Mast cell I N F L A M M A T I O N. Tissue cell. Endothelial cell. Th1/Th17 IL17 IL22
DC IL12, IL23 chemokines, ECM, Co-stimulation IL17, IL22 IFNγ ± Macrophage peptidoglycan lipopolysaccharide heat shock proteins Th1/Th17 IL17 IL22 Cell contact, co-stimulation immune complexes acute phase
More informationRheumatoid Arthritis. Improving Outcomes in RA: Three Pillars. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Modern Management of Common Problems in Rheumatology: Rheumatoid Arthritis Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid
More informationTofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients
doi: 10.2169/internalmedicine.9341-17 Intern Med Advance Publication http://internmed.jp ORIGINAL ARTICLE Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve
More informationActemra. Actemra (tocilizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra
More informationTreating Rheumatologic Disease in Arizona: Good News, Bad News
Treating Rheumatologic Disease in Arizona: Good News, Bad News Jeffrey R. Lisse, M.D. Ethel P. McChesney Bilby Professor of Medicine Chief, Section of Rheumatology University of Arizona School of Medicine
More informationTuberculosis and TNF Inhibitors
Tuberculosis and TNF Inhibitors Sundari Mase MD, MPH Medical Team Lead CDC/DTBE/FSEB January 18, 2011 Objectives Discuss the association between and epidemiology of TNF inhibitors and TB Discuss the challenges
More informationAntirheumatic drugs. Rheumatic Arthritis (RA)
Antirheumatic drugs Rheumatic Arthritis (RA) Disease Modifying Antirheumatic drugs (DMARDs) DMARDs are used in the treatment of rheumatic arthritis RA and have been shown to slow the course of the disease,
More informationRheumatoid Arthritis Update
Rheumatoid Arthritis Update Beth Valashinas, DO, FACOI, FACR Disclosures Speaker for AbbVie Pharmaceuticals Learning Objectives Upon completion of this session, participants should be able to discuss:
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationPRODUCT MONOGRAPH. Pr XELJANZ TM
PRODUCT MONOGRAPH Pr XELJANZ TM Tofacitinib tablets 5 mg tofacitinib (as tofacitinib citrate) Tablets for oral administration Anti-rheumatic, immunomodulator agent Pfizer Canada Inc. 17,300 Trans-Canada
More informationRheumatology Therapeutics: Perioperative DMARD Management, Infection and Malignancy Risks, Vaccination Considerations. Heather Hansen, MD
Rheumatology Therapeutics: Perioperative DMARD Management, Infection and Malignancy Risks, Vaccination Considerations Heather Hansen, MD Objectives Know Broad Categories of Rheumatoid Arthritis Medications
More informationPfizer Announces Modification To Ongoing Tofacitinib FDA Post- Marketing Requirement Study In Patients With Rheumatoid Arthritis
February 19, 2019 Media Contact: Neha Wadhwa M: +1 212-733-2835 E: Neha.Wadhwa@pfizer.com Investor Contact: Charles Triano O: +1 212-733-3901 E: Charles.E.Triano@pfizer.com Pfizer Announces Modification
More informationWARNING: RISK OF SERIOUS INFECTIONS
RA PROGRESSION INTERRUPTED 1 DOSAGE AND ADMINISTRATION GUIDE No structural damage progression was observed at week 52 in 55.6% and in 47.8% of patients receiving KEVZARA 200 mg + MTX or 150 mg + MTX, compared
More informationTofacitinib ( Xeljanz) Marshall Porter & Lauren Ysais
Tofacitinib ( Xeljanz) Marshall Porter & Lauren Ysais Learning Objectives to Take with You A small molecule Janus Kinase (JAK) Inhibitor treatment for moderate to severe rheumatoid arthritis (RA) reduces
More informationActemra (tocilizumab) CG-DRUG-81
Market DC Actemra (tocilizumab) CG-DRUG-81 Override(s) Prior Authorization Approval Duration 1 year Medications Line of Business Quantity Limit Actemra (tocilizumab) vials VA MCD and All L-AGP May be subject
More informationRheumatoid Arthritis. Update in Rheumatoid Arthritis Diagnosis and Therapy. RA: Chronic Joint Destruction and Disability What We Try to Prevent
Rheumatoid Arthritis Update in Rheumatoid Arthritis Diagnosis and Therapy Jonathan Graf, M.D. Associate Professor of Medicine, UCSF Division of Rheumatology, SFGH Director, UCSF Rheumatoid Arthritis Clinic
More informationPRODUCT MONOGRAPH. Pr XELJANZ. Tofacitinib tablets 5 mg tofacitinib (as tofacitinib citrate)
PRODUCT MONOGRAPH Pr XELJANZ Tofacitinib tablets 5 mg tofacitinib (as tofacitinib citrate) XELJANZ XR Tofacitinib extended-release tablets 11 mg tofacitinib (as tofacitinib citrate) Tablets for oral administration
More informationTargeting the JAK/STAT Pathway in Immune-mediated Inflammatory Diseases: Current and Future Directions
Targeting the JAK/STAT Pathway in Immune-mediated Inflammatory Diseases: Current and Future Directions Interim Outcomes Report February 2019 Gilead Sciences, Inc. Grant ID: 02669 Overview Activity Description:
More informationDISCLOSURES. Online A. Infectious Complications of Monoclonal Antibody Therapies 6/22/2012. Cytokine blocking. Lymphocyte depleting.
Online A Infectious Complications of Monoclonal Antibody Therapies Steven M. Holland, M.D. Off-Label Usage None DISCLOSURES Financial Relationships with Relevant Commercial Interests None Resolution: N/A
More informationTechnology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480
Tofacitinib for moderate to severeere rheumatoid arthritis Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480 NICE 2018. All rights reserved. Subject to Notice of rights
More information5/9/2015. Disclosures. Infection in the (non-hiv) Immunocompromised Patient. Outline. Case #1. None. Critical Care Medicine May 2015
Disclosures None Infection in the (non-hiv) Immunocompromised Patient Critical Care Medicine May 2015 Jennifer Babik, MD, PhD Assistant Clinical Professor Division of Infectious Diseases, UCSF Outline
More informationJAK Inhibition in Rheumatoid Arthritis
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationReview. Promise and pitfalls of kinase inhibitors for rheumatoid arthritis. Stanley Cohen
Promise and pitfalls of kinase inhibitors for rheumatoid arthritis Over the last 15 years outcomes for patients with rheumatoid arthritis have dramatically improved. The move towards early aggressive treatment
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationHerpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention
Clinical Review Article Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention Jean-Frédéric Colombel, MD Increased risk of herpes
More informationInflammation, rheumatoid arthritis and cardiovascular disease
Inflammation, rheumatoid arthritis and cardiovascular disease Yvette Meißner, Pharmacoepidemiology, German Rheumatism Research Centre www. chronische-entzuendung.org Outline I. Cardiovascular disease II.
More informationKevzara (sarilumab) NEW PRODUCT SLIDESHOW
Kevzara (sarilumab) NEW PRODUCT SLIDESHOW Introduction Brand name: Kevzara Generic name: Sarilumab Pharmacological class: Interleukin-6 antagonist Strength and Formulation: 150mg/1.14mL, 200mg/1.14mL;
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OLUMIANT safely and effectively. See full prescribing information for OLUMIANT. Neutropenia: Avoid
More informationQUALITATIVE AND QUANTITATIVE COMPOSITION
This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse
More informationOlumiant (baricitinib) tablets
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION OLUMIANTTM (Ō-loo'-mē-ant) baricitinib tablets Read this carefully before you start taking OLUMIANT and each time you
More informationEvaluating Newer Targeted Therapies for Patients with Rheumatoid Arthritis: Addressing Unmet Needs in the Primary Care Practice
Evaluating Newer Targeted Therapies for Patients with Rheumatoid Arthritis: Addressing Unmet Needs in the Primary Care Practice Provided by Integrity Continuing Education, Inc. Supported by an educational
More informationSafety of biologics in rheumatoid arthritis
Placebo-controlled trials of biological therapies in the treatment of rheumatoid arthritis have demonstrated significant efficacy with acceptable safety profiles. Nevertheless, while biologic treatment
More informationPros and Cons of Combination MTX+ Biologics vs Monotherapy with Biologics: the place of immunogenicity
Pros and Cons of Combination MTX+ Biologics vs Monotherapy with Biologics: the place of immunogenicity Daniel E Furst MD University of California in Los Angeles University of Washington University of Florence
More informationWhat I Have Learned Over the Years - Keystone s Top 10 -
What I Have Learned Over the Years - Keystone s Top 10 - Edward Keystone, MD FRCP(C) Professor of Medicine University of Toronto, CANADA Ontario Rheumatology Association Meeting Muskoka, Canada Sunday,
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationReminder. Faculty Affiliation. Complete Session Pre- and Post-Test Complete Online Session Evaluation at End of Session. **Links found in Event App
Overcoming Barriers to the Early Recognition and Diagnosis of Rheumatoid Arthritis in Real-world Practice: Strategies to Expedite Treatment to Remission Provided by Integrity Continuing Education, Inc.
More informationFilm-coated tablet. White, round tablet of 7.9 mm diameter, debossed Pfizer on one side and JKI 5 on the reverse.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
More informationMEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib)
MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) Read this Medication Guide before you start taking XELJANZ and each time you get a refill. There may be new information. This Medication Guide does not
More informationXELJANZ (tofacitinib) tablets for oral administration Initial U.S. Approval: 2012 WARNING: SERIOUS INFECTIONS AND MALIGNANCY
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XELJANZ safely and effectively. See full prescribing information for XELJANZ. XELJANZ (tofacitinib)
More informationPRODUCT MONOGRAPH. Pr XELJANZ. tofacitinib, tablets, oral 5 mg tofacitinib (as tofacitinib citrate) 10 mg tofacitinib (as tofacitinib citrate)
PRODUCT MONOGRAPH Pr XELJANZ tofacitinib, tablets, oral 5 mg tofacitinib (as tofacitinib citrate) 10 mg tofacitinib (as tofacitinib citrate) XELJANZ XR tofacitinib extended-release, tablets, oral 11 mg
More informationRheumatoid Arthritis: Challenges and Opportunities in the Evolving Treatment Landscape ReachMD Page 1 of 9
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationSafety profiles of agents used in the treatment of JIA
Safety profiles of agents used in the treatment of JIA Sampath Prahalad, MD, MSc Marcus Professor of Pediatric Rheumatology Chief, Division of Pediatric Rheumatology Emory University School Of Medicine
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationJakinibs 101: Theory, Practice and Prospects. References 10/27/2013
Jakinibs 101: Theory, Practice and Prospects As a rheumatologist, what do you need to know? Why should you care? Understand what Jaks are Which cytokines care, which don t Mechanisms underlying Jakinib
More informationJAK-STAT Pathway - Role in Immunology. JAK-STAT pathway activation P JAK JAK P P JAK JAK P JAK
Immunology Newsletter May 2018 Volume 2, Issue 1 SMARTImmunology The Immunology Newsletter from SMARTANALYST JAK-STAT athway - Role in Immunology The Janus kinase (JAK) signal transducer and activator
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 17, 2017 Xeljanz Description Xeljanz, Xeljanz
More informationOpportunistic infections. Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India
Opportunistic infections Sanjay Pujari, MD, FIDSA Institute of Infectious Diseases, Pune, India Disclosures Advisory board, Speaker fees: Mylan, Hetero, Cipla ltd Outline Why OI s still occur? Mycobacterial
More information8/11/2015. Febrile neutropenia Bone marrow transplant Immunosuppressant medications
Dean Van Loo Pharm.D. Febrile neutropenia Bone marrow transplant Immunosuppressant medications Steroids Biologics Antineoplastic Most data from cancer chemotherapy Bone marrow suppression Fever is the
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2011 Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2011 presentations Benefit of continuing
More informationDr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru
Dr Daniel Ching Rheumatology Therapeutic Clinical Trials Centre Timaru Therapeutic Advances in Rheumatology GP CME Meeting, Dunedin, 18.08.2013 Dr Daniel Ching, MB FRCP FRACP Consultant Rheumatologist,
More informationGolimumab: a novel anti-tumor necrosis factor
Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies RA: Update on Biologic Therapy and Step-Up or Step-Down Therapeutic Options Learning Objectives Describe the importance of remission
More informationDMARD s in Clinical Practice
DMARD s in Clinical Practice Professor Md. Mahabubul Islam Majumder Professor & Head, Department of Medicine Comilla Medical College, Comilla Bangladesh Disease-modifying antirheumatic drugs (DMARDs) A
More informationPsoriatic Arthritis: New and Emergent Therapies
Psoriatic Arthritis: New and Emergent Therapies Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan Hospital New York, NY, USA DISCLOSURE OF RELEVANT RELATIONSHIPS
More informationTuberculosis in Non-HIV Infected Immunosuppresed Hosts. TNFα inhibitors and beyond
Tuberculosis in Non-HIV Infected Immunosuppresed Hosts TNFα inhibitors and beyond David E. Griffith, MD Assistant Medical Director Heartland National TB Center Professor of Medicine University of Texas
More informationPathogenesis of Rheumatoid Arthritis. Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi: /nrrheum
1 Pathogenesis of Rheumatoid Arthritis 2 Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi:10.1038/nrrheum 2012.23 Biologic therapies used in the treatment of rheumatoid arthritis 3 Etanercept Infliximab
More informationInfectious Complications of. Biologic Therapy
Infectious Complications of Biologic Therapy Nicholas Haddad, MD, FIDSA, CIC Friday November 29, 2013 12th Annual Congress of the Lebanese Society of Gastroenterology Generic Issues Overall, quite safe
More informationPharmacy Accreditation
RHEUMATOID ARTHRITIS: A FOCUS ON REDUCTION OF DISEASE PROGRESSION AND DISABILITY Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP Professor of Clinical Sciences Drake University College of Pharmacy Internal Medicine
More informationMMS Pharmacology Lecture 2. Antirheumatic drugs. Dr Sura Al Zoubi
MMS Pharmacology Lecture 2 Antirheumatic drugs Dr Sura Al Zoubi Revision Rheumatoid Arthritis Definition (RA): is the most common systemic inflammatory disease characterized by symmetrical inflammation
More informationAdvances in the understanding of the pathogenesis of
REPORT Interleukins and Janus Kinases: Emerging Therapeutic Targets in Rheumatoid Arthritis Rupal Mansukhani, PharmD Advances in the understanding of the pathogenesis of autoimmune diseases, such as rheumatoid
More informationEffectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Machado et al. Arthritis Research & Therapy (2018) 20:60 https://doi.org/10.1186/s13075-018-1539-6 RESEARCH ARTICLE Open Access Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort
More informationPreventive Care and Monitoring of the IBD Patient
Preventive Care and Monitoring of the IBD Patient Francis A. Farraye, MD, MSc, FACG Clinical Director, Section of Gastroenterology Director, Inflammatory Bowel Disease Center Boston Medical Center Professor
More informationSlide 1. Slide 2. Slide 3. Complications of Medical Therapy and How to Prevent Them. Objectives. Complications of IBD Medical Therapy
Slide 1 Complications of Medical Therapy and How to Prevent Them Hamed Khalili, M.D., MPH MGH Crohn s and Colitis Center Harvard Medical School Slide 2 Objectives 1. To identify common preventable infectious
More informationLecture: Rheumatology Update on DMARDs in Common Rheumatologic Diseases for the Family Physician. Sco Jay Harris, DO, FACFR
Lecture: Rheumatology Update on DMARDs in Common Rheumatologic Diseases for the Family Physician Sco Jay Harris, DO, FACFR UPDATE ON DMARDS, BIOLOGICALS, CYTOKINE INHIBITORS/B CELL DEPLETIONS/CO-STIMULATION
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Opportunistic Infections and Tuberculosis Risk Management Learning Objectives Define the risks of TB and non-tb opportunistic infections,
More information